Grifols acquires Biotest, expanding catalog of plasma donation centers

Catalan pharma-chemical company Grifols (Nasdaq: GRFS) announced on Wednesday that it had acquired 100% of Biotest Pharmaceuticals  for $286 million, expanding its US presence by almost 1,000 employees.

The deal, which had been stalled until American antitrust bodies could give their approval, will see Grifols acquire Biotest's corporate headquarters in Florida, as well as 22 operative plasma banks in the USA with a further two currently under construction.

The US Federal Trade Commission placed several restrictions on the deal, including ordering Grifols to divest three of its 24 new centers and prohibiting the company from acquiring any ownership stake in ADMA Biologics (Nasdaq: ADMA), a company to which Biotest had previously sold assets.